Figure 5.

Antitumor performance of VNP20009 cells harboring SINGER-azurin in mice bearing B16F10_luci melanoma tumors

(A) Schematic illustrating the experimental design for evaluating the antitumor performance of VNP20009 cells harboring SINGER-azurin against B16F10_luci melanoma tumors. C57BL/6 mice bearing B16F10_luci melanoma tumors received intratumoral injection of PBS alone, US alone (US), untransformed VNP20009 cells (VNP20009), untransformed VNP20009 cells with US (VNP20009+US), VNP20009 cells harboring SINGER-azurin with US induction (SINGER-azurin+US), or VNP20009 cells harboring SINGER-azurin without US induction (SINGER-azurin).

(B) Serial in vivo bioluminescence imaging of B16F10_luci-tumor-bearing mice in the groups depicted in (A). Five representative mice per treatment group are shown.

(C) Bioluminescence quantification of B16F10_luci-tumor-bearing mice treated with different treatments.

(D) Tumor volume measurement in the indicated mouse groups.

(E) Kaplan-Meier curves for mouse survival.

(F) Individual growth curves of B16F10_luci melanoma tumors in different mouse groups.

Data in (C)–(E) are presented as means ± SEM; n = 5 mice per group. p values were calculated by one-way ANOVA with Tukey’s post-test (∗∗∗∗p < 0.0001).